NCT02347657View on ClinicalTrials.gov

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor

PHASE3CompletedINTERVENTIONAL

Enrollment

510

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

January 20, 2017

Study Completion Date

January 20, 2017

Conditions

Cystic Fibrosis

Interventions

DRUG

VX-661 Plus Ivacaftor Combination

FDC tablet, oral use

DRUG

Ivacaftor

Tablet, oral use

DRUG

VX-661 Plus Ivacaftor Combination Placebo

FDC tablet, oral use

DRUG

Ivacaftor placebo

Tablet, oral use

Trial Locations (74)

Unknown

Little Rock

Long Beach

Denver

Orlando

Tampa

Chicago

Peoria

Boston

Minneapolis

St Louis

Manchester

Long Branch

Albuquerque

Albany

Buffalo

New Hyde Park

Rochester

Syracuse

Akron

Columbus

Oklahoma City

Charleston

Sioux Falls

Fort Worth

Tyler

Seattle

Milwaukee

Calgary

Vancouver

Halifax

Toronto

Montreal

Copenhagen O

Marseille

Roscoff

Bordeaux

Lille

Paris

Pierre-Bénite

Heidelberg

Munich

Würzburg

Frankfurt am Main

Giessen

Belfast

Berlin

Cork

Dublin

Genova

Palermo

Roma

Torino

Verona

Groningen

Nijmegen

Rotterdam

The Hague

Utrecht

Barcelona

Madrid

Seville

Valencia

Gothenburg

Stockholm

Uppsala

Bern

Zurich

Exeter

Liverpool

Sheffield

Newcastle upon Tyne

Birmingham

Belfast

London

All Listed Sponsors

lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT02347657 - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor | Biotech Hunter | Biotech Hunter